Axcelead
Fujisawa, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Axcelead provides integrated drug discovery services from target identification to IND filing, specializing in small molecules and novel modalities.
OncologyImmunologyNeuroscienceCardiovascular/Metabolic Disease
Technology Platform
Integrated end-to-end drug discovery platform combining high-throughput screening, omics, bioinformatics, AI-driven in-silico design, and specialized capabilities in targeted protein degradation and RNA-targeted small molecules.
Opportunities
Growth opportunities include expanding partnerships with Western biotechs seeking specialized expertise in novel modalities like TPDs, and leveraging their pharmaceutical heritage to capture more integrated discovery deals from virtual and small biotech companies.
Risk Factors
Key risks include dependence on the Japanese market, competition from larger global CROs with broader geographic reach, and potential client concentration if reliant on few major partnerships.
Competitive Landscape
Competes with global preclinical CROs like Evotec and WuXi AppTec, but differentiates through integrated Japan-based operations, pharmaceutical heritage from Takeda, and specialized expertise in complex modalities like targeted protein degradation.